Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions

Inclusion criteria * Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone lesion * No treatment with bisphosphonates within 6 months prior to inclusion into the study * Good health status (ECOG Performance status 0-2) Exclusion criteria * Patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening * Abnormal renal function * History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism * Pregnancy and lactation * Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g..extraction, implants)